GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00452127
A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 578
- Registration Number
- NCT00443651
A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)
Completed
- Conditions
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2015-03-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1026
- Registration Number
- NCT00443443
- Locations
- 🇺🇸
Rheumatology Associates, Dallas, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸MIMA Century Research Associates, Melbourne, Florida, United States
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00434434
A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT00434252
A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00434278
- Locations
- 🇺🇸
Ventura County Medical Ctr, Ventura, California, United States
🇺🇸Pulm & Critical Care Assoc, Jacksonville, Florida, United States
🇺🇸Morristown Memorial Hospital, Morristown, New Jersey, United States
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00434226
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT00434642
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00434356
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1015
- Registration Number
- NCT00406419
- Locations
- 🇺🇸
Trial Information Support Line, South San Francisco, California, United States
© Copyright 2024. All Rights Reserved by MedPath